CHM-029 / CHARM Therapeutics - LARVOL DELTA

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Charm Therapeutics

First-in-human • Monotherapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • KMT2A • NPM1 • NUP98

CHARM Therapeutics advances CHM-029, a next-generation menin inhibitor designed to overcome resistance mutations, as its first clinical candidate for acute myeloid leukaemia (AML) (GlobeNewswire) - "AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutation. First-in-human trials expected to begin in Q2 2026."

First-in-human • New trial • Preclinical • Acute Myelogenous Leukemia